{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "Pharmacologic Substance[C1909]|Biological Agent[C307]|Recombinant Cytokine[C1283]" in comments (approximate match)
Class:
PROTEIN
Status:
Investigational
Source:
NCT00001564: Phase 2 Interventional Completed Ewing's Sarcoma
(1996)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00873756: Phase 1 Interventional Completed Metastatic Colorectal Cancer
(2009)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00031733: Phase 2 Interventional Completed Intraocular Melanoma
(2002)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00004070: Phase 1/Phase 2 Interventional Completed Head and Neck Cancer
(1999)
Source URL:
Class:
PROTEIN
Status:
US Previously Marketed
Source:
Neumega
(1997)
Source URL:
First approved in 1997
Source:
Neumega
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
Japan:Celmoleukin (Genetical Recombination)
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
Japan:Interferon Gamma-1a (Genetical Recombination)
Source URL:
Class:
PROTEIN
